# US 2026/0130919 A1 · Pralatrexate and cop combination for the treatment of patients with peripheral t cell lymphoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0130919 A1
- Document ID: US20260130919A1
- Status: Published application
- Kind: A1
- Application number: 19/440,054
- Filed: 2026-01-05
- Published: 2026-05-14
- Earliest claimed: 2023-07-07
- Assignees: Acrotech Biopharma Inc.
- Applicants: Acrotech Biopharma Inc.
- Inventors: Ashish Anvekar
- Web page: https://patentgrep.com/patent/US20260130919A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07F 9/65846: {the phosphorus atom being part of a six-membered ring which may be condensed with another ring system}
- C07J 5/0053: {not substituted in position 16}
- C07D 475/08: with a nitrogen atom directly attached in position 2
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07J: STEROIDS (seco-steroids C07C)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The disclosure provides compositions and methods for treating peripheral T-cell lymphoma (PTCL) using a combination of Pralatrexate and COP.

## Claims

### Claim 1

A method for treating peripheral T-cell lymphoma (PTCL) comprising administering to a subject in need thereof a combination comprising Cyclophosphamide, Vincristine, Prednisone and Pralatrexate,
wherein the combination does not comprise doxorubicin.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the combination consists of Cyclophosphamide, Vincristine, Prednisone and Pralatrexate.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the administering occurs in a three-week cycle optionally comprising a drug holiday.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the Cyclophosphamide, Vincristine, Prednisone and Pralatrexate are independently administered daily, weekly, or once every two weeks for at most two weeks of the three-week cycle, such that the three-week cycle contains a weeklong drug holiday.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the three-week cycle is repeated from at least 1 to 10 times.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the three-week cycle is repeated one time, two times, three times, four times, five times, six times, seven times, eight times, nine times, or ten times.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the Pralatextrate is administered on days 1 and 8 of a treatment cycle.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the Cyclophosphamide and/or Vinicristine, and/or Predinisone is administered daily for a time period within the treatment cycle.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the Cyclophosphamide and/or Vinicristine, and/or Predinisone is administered daily for days 1-15, or for days 1-10, or for days 1-8, or for days 1-6, or for days 1-5, or for days 1-4, or for days 1-3 of the treatment cycle.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method comprises a 21 day treatment cycle, the treatment cycle comprising:
a) administering Pralatrexate in a dosage of at least about 10 mg/m2 intravenously on day 1 and day 8;
b) administering Cyclophosphamide in a dosage of at least about 700 mg/m2 intravenously and Vincristine in a dosage of at least about 1 mg/m2 intravenously, on day 1,
wherein the Cyclophosphamide and/or Vinicristine are independently optionally administered following or concomitantly with the administration of Pralatrexate on day 1; and
c) administering Prednisone in a dosage of at least about 50 mg orally on each of day 1 to day 5, wherein the prednisone is optionally administered on day 1 following the administration of Pralatrexate.

### Claim 11 (depends on 10)

The method of claim 10, wherein the 21 day cycle is repeated between 1 to 6 times.

### Claim 12 (depends on 10)

The method of claim 10, wherein the treatment cycle comprises at least one of:
a) administering Pralatrexate in a dosage of about 20 to about 30 mg/m2 intravenously on day 1 and day 8;
b1) administering Cyclophosphamide in a dosage of from about 700 mg/m2 to about 800 mg/m2 on day 1;
b2) administering Cyclophosphamide in a dosage of about 750 mg/m2 intravenously on day 1;
b3) administering Vincristine in a dosage of from about 1 mg/m2 to about 2 mg/m2 intravenously on day 1,
b4) administering Vinicristine in a dosage of about 1.2 mg/m2 to about 1.6 mg/m2 intravenously on day 1,
b5) administering Vinicristine in a dosage of about 1.4 mg/m2, intravenously, on day 1,
c1) administering Prednisone in a dosage of from about 50 mg to 150 mg on day 1 following administration of Pralatrexate;
c2) administering Prednisone in a dosage of from about 80 mg to about 120 mg on day 1 following administration of Pralatrexate, and
c3) administering Prednisone in a dosage of about 100 mg orally on day 1 following administration of Pralatrexate.

### Claim 13

A kit comprising Pralatrexate, Cyclophosphamide, Vincristine, and Prednisone, wherein said kit does not comprise doxorubicin.

### Claim 14 (depends on 13)

The kit of claim 13, wherein the Pralatrexate, is formulated separately from the Cyclophosphamide, the Vincristine, and the Prednisone.

### Claim 15 (depends on 13)

The kit of claim 13, wherein the kit comprises a first pharmaceutical composition comprising about 20 to 30 mg/m2 Pralatrexate and a first pharmaceutically acceptable excipient and/or a second pharmaceutical composition comprising about 500-1000 mg/m2 Cyclophosphamide and a second pharmaceutically acceptable excipient, and/or a third pharmaceutical composition comprising about 1-3 mg/m2 Vinicristine and a third pharmaceutically acceptable excipient, and/or a fourth pharmaceutical composition comprising about 50-150 mg Prednisone and a fourth pharmaceutically acceptable excipient.

### Claim 16 (depends on 15)

The kit according to claim 15, wherein at least two of the first pharmaceutical composition, second pharmaceutical composition, third pharmaceutical composition and fourth pharmaceutical composition are the same pharmaceutical composition.

### Claim 17 (depends on 15)

The kit of claim 15, wherein the first pharmaceutical composition is an intravenous composition, the second pharmaceutical composition is an intravenous composition, the third pharmaceutical composition is an intravenous composition, the fourth pharmaceutical composition is an oral composition, or a combination thereof.

### Claim at position 18

18-20. (canceled)

### Claim 21 (depends on 15)

The kit of claim 15, wherein the second composition comprises about 700-800 mg/m2 Cyclophosphamide, the third composition comprises about 1-2 mg/m2 Vinicristine, the fourth composition comprises about 75-125 mg Prednisone, or a combination thereof.

### Claim 22 (depends on 15)

The kit of claim 15, wherein the second composition comprises about 750 mg/m2 Cyclophosphamide, the third composition comprises about 1.4 mg/m2 Vinicristine, the fourth composition comprises about 100 mg Prednisone, or a combination thereof.

### Claim 23

(canceled)

### Claim 24 (depends on 15)

The kit of claim 15, wherein the third composition comprises about 1.2-1.6 mg/m2 Vinicristine.

### Claim at position 23

25-27. (canceled)
